A Changing Regulatory Landscape For Weight Loss Drugs
Prescriptions for a new class of drugs to treat obesity surged exponentially in 2023. Originally approved for treatment of Type 2 diabetes, glucagon-like peptide-1 receptor agonist drugs, or GLP-1s, such as...To view the full article, register now.
Already a subscriber? Click here to view full article